

Amendment of the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

1. (Currently Amended) A process for extending lifespan of a mouse, a human, or a cell thereof ~~mammal or a mammalian cell~~ beyond a generic expected lifespan for said mouse, said human, or said cell thereof ~~mammal or mammalian cell~~ comprising administering to said mouse, said human, or said cell thereof ~~mammal or mammalian cell~~ a therapeutically effective amount of a composition comprising a C₆₀ compound or a combination of such C₆₀ compounds, said C₆₀ compounds being selected from the group consisting of *e,e,e* C₆₀(C(COOH)₂)₂(CHCOOH), *e,e,e* C₆₀(CHCOOH)₃, C₆₀(C(COOH)₂)_n, pharmaceutically acceptable salts of any of the foregoing, pharmaceutically acceptable esters of any of the foregoing, and pharmaceutically acceptable amides of any of the foregoing, wherein the C adjacent the C₆₀ moiety in each of the foregoing formulae is directly bonded to two adjacent carbons of the C₆₀ moiety, wherein n = 1, 2, or 3, and wherein said mouse, said human, or said cell thereof ~~mammal or mammalian cell~~ is not selected for a disability, thereby extending the lifespan of said mouse, said human, or said cell thereof ~~mammal or said mammalian cell~~ beyond the generic expected lifespan for said mouse, said human, or said cell thereof ~~mammal or said mammalian cell~~ by up to about 20% [[32%]].

2. (Canceled)

3. (Previously Presented) The process of Claim 1 wherein said at least one said C₆₀ compound is administered in a composition further comprising a pharmaceutically acceptable carrier.


4. (Previously Presented) The process of Claim 1 where n is 3.
5. (Previously Presented) The process of Claim 4 wherein said C₆₀ compound is *e,e,e* C₆₀(C(COOH)₂)₃.
6. (Previously Presented) The process of Claim 1 wherein said C₆₀ compound is administered intravenously, intramuscularly, subcutaneously or orally.
7. (Previously Presented) The process of Claim 6 wherein said C₆₀ compound is administered intravenously, intramuscularly or subcutaneously in an amount of at least 0.1 mg/kg.
8. (Previously Presented) The process of Claim 7 wherein said C₆₀ compound is administered intravenously, intramuscularly or subcutaneously in an amount of about 3 mg/kg.
9. (Previously Presented) The process of Claim 6 wherein said C₆₀ compound is administered orally in an amount of at least 0.1 mg/kg.
10. (Previously Presented) The process of Claim 6 wherein said C₆₀ compound is administered orally in an amount of about 15 mg/kg.
11. (Previously Presented) The process of Claim 7 wherein said C₆₀ compound is administered daily.
12. (Previously Presented) The process of Claim 9 wherein said C₆₀ compound is administered daily.
- 13.-69. (Canceled)
70. (Currently Amended) The process as set forth in Claim 1 wherein an expected lifespan of said mouse, said human, or said cell thereof ~~the mammal or mammalian cell~~ prior to

Appl. No. 10/083,283
Response to Notice of Non-Compliant
Amendment dtd. 6/27/06
Atty. Docket No.: 53047-31628

PATENT

treatment is the generic expected lifespan for said mouse, said human, or said cell thereof
~~mammal or mammalian cell.~~

Respectfully submitted,

A handwritten signature in black ink, appearing to read "C. P. Romano", written over a horizontal line.

Charles P. Romano, Reg. No. 56,991
Thompson Coburn LLP
One US Bank Plaza
St. Louis, MO 63101
314-552-6255
314-552-7255 (Fax)

Dated: July 13, 2006